[EuroTimes] Drug helps relieve DRY EYEMay 10, 2019
BRM421 interrupts the dry eye vicious cycle and has the potential to control inflammation induced by DAMP, reducing subsequent tissue oedema and damage.[Read more ...]
Dengue Diseases: from Epidemiology to TreatmentNovember 20, 2015
Dengue Diseases: from Epidemiology to Treatment
BRIM appearing on BioCentury: How BRIM is bridging a translational science gap in TaiwanNovember 16, 2015
Bridge to POC
BRIM Biotechnology Inc. has assembled a team of translational science veterans to fill what it sees as a gap in Taiwanese drug development capabilities. The company plans to bring in preclinical projects with global commercialization potential and develop them through Phase Ia or IIb proof of concept, then sell them or find a partner to complete development outside of Taiwan or Asia.
BRIM seeks global rights to programs from academic groups, multinationals and biotechs. The company has four preclinical programs, including two cancer biologics and one dengue fever collaboration with a Johnson & Johnson unit.
2015-06-11 BRIM Biotechnology Announces Strategic Collaboration with Johnson & Johnson Innovation to Advance New Treatments for DengueJune 11, 2015
TAIPEI, June 11, 2015 /PRNewswire/ — BRIM Biotechnology, Inc. (“BRIM”), announced today that it has entered a Collaboration, Option and License Agreement with Janssen Pharmaceutica N.V. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement, which was facilitated by Johnson & Johnson Innovation, the parties will pursue the research, development and commercialization of certain compounds identified by Janssen that are targeted for dengue indications.
Dr. Haishan Jang, BRIM’s President and CEO, stated, “We are extremely excited and enthusiastic about working with Janssen in developing effective treatment for dengue. There is a high unmet medical need in dengue, especially in Asia. With Janssen’s experienced Infectious Diseases team and BRIM’s core competencies in translational sciences and integrated operation management in Asia, we are confident at progressing the compounds toward a high quality affordable drug candidate for Dengue disease.”
About Dengue Disease
Dengue is ranked by WHO as the most important mosquito-borne viral disease, with approximately 2.5 billion people live in dengue endemic countries, and is seeing rapid and ongoing expansion related to increasing global spread of the viral vector. While WHO estimates suggest 50-100 million dengue infections occur annually, recent data from 2010 reported up to 390 million infections annually, with almost 100 million having symptoms of infection (Bhatt et al 2013, Nature). Global warming and intercontinental flights fuel the global spreading of this disease. Dengue is the leading cause for children hospitalization in Asia. The first dengue infection is generally a self-limiting, acute febrile illness. Subsequent infection with a different serotype can lead to severe disease (Dengue Hemorrhagic Fever), Dengue Shock Syndrome and even death.
BRIM (Beyond Research and Innovative Medicines), a preclinical/clinical development company focused on using translational sciences to develop affordable and high quality medicines, began operating in August 2013 and is based in Taipei, Taiwan. With a fully integrated Asia-based R&D operation team and a US-based senior scientific team experienced in all functional areas of drug development, BRIM is well poised to bring new therapies to the market.
For more information, please visit www.brimbiotech.com
Ms. Mei-Hui Kuo
TEL: +886-2-2788-8090 ext.110
SOURCE BRIM Biotechnology Inc.